Breast Cancer Clinical Trials

Showing 2261-2280 of 4,817 trials

Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer

NCT05033769

After progression of disease after one chemotherapy, metastatic breast cancer patients will be randomized 1:1 to one of the following treatment arms: Arm A. Eribulin Arm B. Paclitaxel Blood draws for immune analysis will be performed before start of therapy, on day 1 of cycle 2 and on day 21 of cycle 4 (end of therapy) for the primary study aim. Patients will be treated under study conditions for a maximum of 4 therapy cycles.

Breast Cancer FemaleNeoplasm, BreastBreast Cancer Metastatic

Institut fuer Frauengesundheit82 participantsStarted Mar 2021

Tübingen, Baden-Wurttemberg, Germany • Erlangen, Bavaria, Germany

UNKNOWNNA

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA

NCT05814224

The purpose of the study is to determine the diagnostic role of ctDNA when used to monitor metastatic breast cancer (MBC) during first-line endocrine therapy.

Hormone Receptor Positive Breast CarcinomaBreast NeoplasmsNeoplasms, Breast+4 more

Centro di Riferimento Oncologico - Aviano164 participantsStarted May 2018

Bergamo, Bergamo, Italy • Aviano, Pordenone, Italy • Brescia, Italy +4 more locations

Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA

Related Searches

Mechanism Exploration of Anti-HER-2 Small-molecule Tyrosine Kinase Inhibitor-related Diarrhea and Establishment of Prevention and Treatment Model(Measure)

Moving on After Breast Cancer Plus- for Breast Cancer Survivors

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Alternative Exercise Program to Improve Skeletal Muscle Function and Fatigue in Cancer Survivors

Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Deformable Image Registration for Breast Adaptive Tomotherapy

Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer

Aerobic Training in Metastatic Breast Cancer

Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia

Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer

Optical Spectroscopy in Evaluating Tumor Margins in Patients Who Have Undergone Surgery for Breast Tumors

Automated Breast Ultrasound Screening

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

Automated Low Dose Risk Assessment Mammography (ALDRAM)

Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC

Epidemiology of Breast Cancer in Women Based on Diagnosis Data From Oncologists and Breast Surgeons in Algeria